NASCACELL and CAPSULUTION start joint development program
Novel development for target validation, drug discovery and therapy
Specifically, the partners will couple aptamers to functional peptide nanoparticles with subsequent analyses in cellular assays as well as animal studies. The nano-particles and -capsules are also suitable to deliver drug development candidates and will be optimized in this direction.
„We expect additional growth of our aptamer service business, in particular for intracellular applications, from this combination of our gene transfer know how and Capsulution`s established formulation expertise. Furthermore, these new methods will also be applicable for other applications such as therapeutic RNAi. Capsulution with an established track record of its innovative technology is an ideal partner in this endeavour, “ says Dr. Ernst Boehnlein, CEO of NascaCell.
In addition to the application of its technologies by its partner, Capsulution expects gain of additional know how. ”NascaCell has a unique experience in the areas of target validation and drug discovery from which we can benefit in the development of custom-tailored solutions,” says Alexander Herrmann, CFO of Capsulution.
Capsulution Pharma AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.
About NascaCell Technologies AG – www.nascacell.com
NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the MicrobodyTM technology.
Diese Pressemitteilungen könnten Sie auch interessieren
Weitere Informationen zum Thema "Forschung und Entwicklung":
So beeinflusst Machine Learning die Business Intelligence
In meinem Arbeitsleben habe ich Business Intelligence (BI) von beiden Seiten gesehen – als Softwareentwickler und als Anwender. So habe ich einen Einblick in die Herausforderungen gewonnen, mit denen die jeweiligen Seiten konfrontiert sind – bei der Entwicklung sowie bei der Nutzung von BI-Lösungen.Weiterlesen